Skip to main content

Table 2 Risk of bias for included studies

From: The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials

Study

Random sequence generation

Allocation concealment

Blinding of participants and personnel

Blinding of outcome assessment

Incomplete outcome data

Selective reporting

other bias

Pujade-Lauraine2010 [13]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk

Gladieff2012 [14]

Low risk

Unclear risk

High risk

Low risk

Low risk

Low risk

Low risk

Mahner2014 [15]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk

Bafaloukos2010 [16]

Low risk

Low risk

Unclear risk

Low risk

Low risk

Low risk

Low risk

Mutch2007 [17]

Low risk

Low risk

High risk

Unclear risk

Unclear risk

High risk

Low risk

Ferrandina2008 [18]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk

Vergote2009 [19]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk

Colombo2012 [20]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk

Banerjee2018 [21]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk

Kaye2012 [22]

Low risk

Low risk

High risk

Low risk

Low risk

Low risk

Low risk